TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01201278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin LISPRO
Description: Subcutaneous insulin lispro 8 U
Study: NCT06295523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray
Description: Participants will receive water spraying on their body throughout the climate chamber exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will NOT receive water spraying on their body throughout the climate exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will NOT receive water spraying on their body throughout the climate exposure.
Study: NCT06366763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires to assess the quality of life (CIVIQ-14 and VCSS scores )
Study: NCT05969535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Birth preparation education according to travelbee human-human relations theory
Description: human-to-human communication and psychoeducation-assisted birth preparation training
Study: NCT05997420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR Program
Description: In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
Study: NCT06186063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline) infusion
Description: At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.
Study: NCT05264506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2 COC
Description: Dosage Formulation: Film-coated Tablet Unit Dose Strength: Nomegestrol acetate (NOMAC) 2.5 mg and estradiol (E2) 1.5 mg; Each blister strip contains 28 tablets: 24 tablets with the active drug (number 1 to 24) and 4 tablets with placebo (number 25 to 28).~Dosing Instructions: oral. Take 1 tablet daily at about the same time as directed.
Study: NCT06169982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC
Study: NCT06126341

Intervention type: OTHER
Intervention: Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM
Description: Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.

Intervention type: OTHER
Intervention: Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM
Description: Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.

Intervention type: BEHAVIORAL
Intervention: Hospital Anxiety and Depression Scale
Description: Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire

Intervention type: BEHAVIORAL
Intervention: Hospital Anxiety and Depression Scale
Description: Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire

Intervention type: BEHAVIORAL
Intervention: Duke-UNC Functional Social Support Questionnaire
Description: A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.

Intervention type: BEHAVIORAL
Intervention: Duke-UNC Functional Social Support Questionnaire
Description: A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.

Intervention type: BEHAVIORAL
Intervention: Distress Thermometer
Description: The Distress Thermometer is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress

Intervention type: BEHAVIORAL
Intervention: Distress Thermometer
Description: The Distress Thermometer is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress

Intervention type: BEHAVIORAL
Intervention: FACT-BMT
Description: The FACT-BMT Version 4.0 is a 37 item self-report questionnaire that measures the effect of cancer on Quality of Life domains
Study: NCT05957822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA
Description: Tranexamic acid injection 8-10mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA
Description: Tranexamic acid injection 8-10mg/kg

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TEG6
Description: performing thromboelastography (TEG6)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TEG6
Description: performing thromboelastography (TEG6)
Study: NCT05786768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single infusion of Rituximab
Description: single infusion of Rituximab 375 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single infusion of Obinutuzumab
Description: single infusion of Obinutuzumab 300mg/1.73 m2
Study: NCT00925327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking with riboflavin/UVA light
Description: Corneal collagen cross-linking with riboflavin/UVA light
Study: NCT04947319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Part A: Tirabrutinib 480 mg, taken orally, once a day on an empty stomach. Tirabrutinib treatment may be continued until disease progression or clinically unacceptable toxicity is observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Part B, Arm 1 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an MTR induction regimen. Tirabrutinib with MTR treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed.~For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Part B, Arm 2 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an R-MPV induction regimen. Tirabrutinib with R-MPV treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed.~For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment.
Study: NCT04849091

Intervention type: DEVICE
Intervention: iReadMore
Description: Digital Alexia Therapy
Study: NCT05697276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
Study: NCT05225701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic guided internet-delivered intervention with synchronous assistance
Description: Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists). The function of the psychological advisor is to motivate, guide and listen to the doubts and comments of each participant by providing a weekly session of one hour in individual online format, in addition to the review of the module in platform in self-suggestive format.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic self-guided internet-delivered intervention
Description: Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each module will include exercises and tasks for the practice of each technique. Automatic emails with notifications will be sent to access the program when participants have not entered in the last 15 days.
Study: NCT06235034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic CT
Description: radiotherapy will be designed on diagnostic CT. If plan is of sufficient quality, RT will be delivered to patient
Study: NCT06044168

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Leucine
Description: 150mg/kg body mass/day
Study: NCT05467995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK111
Description: AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK111
Description: AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK111
Description: AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
Study: NCT06126341

Intervention type: BEHAVIORAL
Intervention: FACT-BMT
Description: The FACT-BMT Version 4.0 is a 37 item self-report questionnaire that measures the effect of cancer on Quality of Life domains

Intervention type: BEHAVIORAL
Intervention: Psychosocial Assessments of Candidates for Transplantation
Description: The PACT scale is a single page 10-item rating scale with high inter-rater reliability that has been used extensively in solid organ transplantation

Intervention type: BEHAVIORAL
Intervention: Psychosocial Assessments of Candidates for Transplantation
Description: The PACT scale is a single page 10-item rating scale with high inter-rater reliability that has been used extensively in solid organ transplantation
Study: NCT06277661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMI PODS
Description: MOMI PODS is an innovative, dyadic model of PP primary care. Informed by the Chronic Care Model (CCM) and extensive stakeholder engagement, the MOMI PODS suite of services addresses four primary domains, with a focus on preventing PRM and eliminating SES, racial, and ethnic disparities in PRM. First, MOMI PODS is a dyadic model of care, with mothers and infants cared for in tandem throughout the PP year, and beyond. Second, MOMI PODS was strategically designed to facilitate a coordinated obstetric to PP primary care transition. Third, MOMI PODS is delivered in a way that promotes tailored, evidence-based care informed by the obstetric history. Fourth, MOMI PODS systematically integrates clinical and supportive care to concurrently address clinical and psychosocial needs, with MOMI PODS engagement extending beyond the typical referral process to facilitate direct access to needed resources and empower patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Usual care will be enhanced in by implementing an enhanced PP care handoff as an adaptation of typical institutional discharge procedures. Specifically, under current processes, birthing parents are asked to provide the name of their infant's pediatrician during the L\&D admission, must provide the name of their infant's pediatrician prior to discharge, and are assisted with identifying a pediatrician throughout this process as needed. Alternatively, under current processes, mothers are reminded to seek PP care but not required to identify the location of care or assisted with doing so. As a component of EUC, we'll provide participants with information about our 7 EUC sites and actively assist with identifying their preferred location of care and scheduling PP care. Our research team will also engage with EUC recipients throughout the study period to encourage engagement and study retention through small care packages and hand-written notes, as well as data collection.
Study: NCT04571502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My PATI ( Person Assisted Touchscreen Interface)
Description: My PATI was designed to support communication between PWD and their caregiver, and healthcare provide; promotes person centered care by giving the PWD their voice and specifically by supporting the PWD in expressing their experiences , needs, preferences in care activities (e.g., food choices, clothing), and entertainment ( personalized pictures, videos , and music). My PATI has multiple features including allowing the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the healthcare provider. The clinical trial evaluates the impact of the My PATI interface that relies on touchscreen technology ( two interfaces one for PWD that can be used independently or with assistance, and a 2nd caregiver interface for customization ). The comparison group will receive usual care.
Study: NCT05040568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expanded CB-NK cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05858892

Intervention type: OTHER
Intervention: usual care
Description: usual care(rehabilitation program)
Study: NCT05107570

Intervention type: OTHER
Group type: OTHER
Intervention: Cold exposure
Description: Cold air exposure (\~ 9°C, maximum 1 hour duration)

Intervention type: OTHER
Group type: OTHER
Intervention: Cold exposure
Description: Cold air exposure (\~ 9°C, maximum 1 hour duration)
Study: NCT06674525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 626
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 626
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 626
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 626
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 626
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 626
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection
Study: NCT06223646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2003 CAR T-cells
Description: KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2003 CAR T-cells
Description: KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2003 CAR T-cells
Description: KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KQ-2003 CAR T-cells
Description: KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
Study: NCT05041790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Alfoscerate
Description: Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
Study: NCT06704724

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)
Study: NCT05308134

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard fortification
Description: Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Target fortification
Description: Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BUN adjustable fortification
Description: BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
Study: NCT05372991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-009
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
Study: NCT05881837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: HRS9531 injection: dose level 1 for 32 weeks、level 2 for 20 weeks
Study: NCT05372991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-009
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-009
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
Study: NCT05587933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy
Description: cholecystectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antispasmodic
Description: Antispasmodic
Study: NCT06406959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominal plane block (TAP block)
Description: Unilateral US-guided TAP-block lateral approach with 20 ml 0,375% Levobupivacaine before incision